iCAD, Inc. (NASDAQ:ICAD - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.02 and traded as high as $2.22. iCAD shares last traded at $2.21, with a volume of 180,670 shares changing hands.
Analyst Ratings Changes
Separately, StockNews.com raised iCAD from a "sell" rating to a "hold" rating in a report on Thursday, February 20th.
Check Out Our Latest Stock Analysis on iCAD
iCAD Stock Performance
The stock has a market capitalization of $58.65 million, a P/E ratio of -17.00 and a beta of 1.95. The firm's fifty day simple moving average is $2.61 and its 200 day simple moving average is $2.02.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in ICAD. waypoint wealth counsel lifted its stake in iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares during the last quarter. Thompson Davis & CO. Inc. bought a new stake in shares of iCAD during the 4th quarter worth $31,000. PKS Advisory Services LLC acquired a new stake in iCAD in the fourth quarter valued at about $53,000. Wells Fargo & Company MN grew its position in iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock valued at $72,000 after acquiring an additional 13,402 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in iCAD during the fourth quarter worth about $92,000. 24.61% of the stock is owned by institutional investors.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
